POMBILITI
Total Payments
$5.0M
Transactions
581
Doctors
29
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $2.2M | 217 | 11 |
| 2023 | $2.8M | 364 | 21 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $4.7M | 486 | 93.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $169,644 | 24 | 3.4% |
| Consulting Fee | $148,634 | 48 | 3.0% |
| Travel and Lodging | $11,404 | 15 | 0.2% |
| Education | $287.60 | 8 | 0.0% |
Payments by Type
Research
$4.7M
486 transactions
General
$329,970
95 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With LOPD | Amicus Therapeutics, Inc. | $2.7M | 0 |
| AT2221-03 | Amicus Therapeutics, Inc. | $284,132 | 0 |
| First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2263 | Amicus Therapeutics, Inc. | $237,980 | 0 |
| First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2250 | Amicus Therapeutics, Inc. | $121,466 | 0 |
| First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2232 | Amicus Therapeutics, Inc. | $108,660 | 0 |
| First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2222 | Amicus Therapeutics, Inc. | $105,482 | 0 |
| First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2264 | Amicus Therapeutics, Inc. | $86,767 | 0 |
| First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2243 | Amicus Therapeutics, Inc. | $73,512 | 0 |
| First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2252 | Amicus Therapeutics, Inc. | $70,429 | 0 |
| First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2265 | Amicus Therapeutics, Inc. | $66,437 | 0 |
| First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2241 | Amicus Therapeutics, Inc. | $58,883 | 0 |
| First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2246 | Amicus Therapeutics, Inc. | $54,645 | 0 |
| First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2256 | Amicus Therapeutics, Inc. | $44,394 | 0 |
| First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2266 | Amicus Therapeutics, Inc. | $43,667 | 0 |
| First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2234 | Amicus Therapeutics, Inc. | $42,344 | 0 |
| First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2242 | Amicus Therapeutics, Inc. | $39,608 | 0 |
| First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2240 | Amicus Therapeutics, Inc. | $38,804 | 0 |
| First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2227 | Amicus Therapeutics, Inc. | $35,635 | 0 |
| First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2251 | Amicus Therapeutics, Inc. | $33,889 | 0 |
| A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18 | Amicus Therapeutics, Inc. | $32,700 | 0 |
Top Doctors Receiving Payments for POMBILITI
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Durham, NC | $4.8M | 510 |
| , MD | Neurology | Orange, CA | $40,253 | 10 |
| Priya Kishnani | Pediatrics | Durham, NC | $21,830 | 7 |
| , MD | Internal Medicine | Livingston, NJ | $14,200 | 6 |
| , M.D | Pediatrics | Hershey, PA | $10,802 | 4 |
| , MD | Pediatric Cardiology | Gainesville, FL | $8,783 | 6 |
| , M.D., M.P.H | Clinical Genetics (M.D.) | Salt Lake City, UT | $7,891 | 3 |
| , M.D | Neuromuscular Medicine | Kansas City, KS | $7,353 | 1 |
| , M.D | Specialist | Phoenix, AZ | $7,000 | 2 |
| , M.D | Neurology | Phoenix, AZ | $5,387 | 3 |
| , M.D | Neuromuscular Medicine | Aurora, CO | $5,000 | 2 |
| , M.D | Neurology | Portland, OR | $4,662 | 2 |
| , MD | Endocrinology, Diabetes & Metabolism | Dallas, TX | $3,879 | 1 |
| , M.D | Neurology | Portland, OR | $2,983 | 2 |
| , M.D | Neurology | Philadelphia, PA | $2,800 | 2 |
| , DO | Clinical Biochemical Genetics | Philadelphia, PA | $2,432 | 1 |
| , MD | Pediatrics | Valhalla, NY | $2,400 | 1 |
| , APNP | Family | Milwaukee, WI | $1,949 | 2 |
| , M.D | Pediatrics | Minneapolis, MN | $1,920 | 2 |
| , MD | Neuromuscular Medicine | Los Angeles, CA | $1,864 | 1 |
| , M.D | Internal Medicine | Detroit, MI | $1,760 | 1 |
| , MD | Neurology | Gainesville, FL | $1,760 | 1 |
| , M.D | Medical Biochemical Genetics | Palo Alto, CA | $1,533 | 2 |
| , M.D | Neurology | Los Angeles, CA | $1,044 | 1 |
| , M.D | Student in an Organized Health Care Education/Training Program | Chicago, IL | $590.00 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $5.0M
- Total Doctors 29
- Transactions 581
About POMBILITI
POMBILITI is a drug associated with $5.0M in payments to 29 healthcare providers, recorded across 581 transactions in the CMS Open Payments database. The primary manufacturer is Amicus Therapeutics, Inc..
Payment data is available from 2023 to 2024. In 2024, $2.2M was paid across 217 transactions to 11 doctors.
The most common payment nature for POMBILITI is "Unspecified" ($4.7M, 93.4% of total).
POMBILITI is associated with 20 research studies, including "A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With LOPD" ($2.7M).